Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Alcon claims new 5-HT2 receptor agonists and their use as IOP lowering agents

April 20, 2004

New prostanoid EP4 agonists for glaucoma therapy claimed by Merck Frosst

April 19, 2004

Orphan drug status for microplasmin in pediatric eye surgery

April 6, 2004

SnET2-PDT NDA submitted for AMD

April 5, 2004

Lupin to promote Zymar to U.S. pediatricians

April 2, 2004

ThromboGenics and NuVue collaborate on plasmin products for visual disorders

March 16, 2004

Iquix receives FDA approval for bacterial corneal ulcer

March 15, 2004

VEGF Trap enters clinical development program

March 12, 2004

Positive results from Xibrom phase III studies

March 11, 2004

Additional phase III data in support of TTFC

March 10, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...